FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Released May 17, 2017
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
Be part of the knowledge.™FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
Choose a format
Media formats available:
Facebook Comments